We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A&G Pharmaceutical has entered into an agreement with a South Korean biotech business that could be worth up to $8.4 million plus royalties for the small pharmaceutical company.
Thursday morning, Repligen Corp., a biopharmaceutical company, revealed fourth quarter results, reporting a net loss that widened on higher operating expenses and on a 4% decline in revenues.
Cubist Pharmaceuticals, Inc. today announced that it will redeem its 5 1/2% Convertible Subordinates Notes due 2008 on June 28, 2006, in accordance with the terms of the indenture governing the notes.
The FDA has issued a warning letter to Sandoz citing violations of the Federal Food, Drug, and Cosmetic Act's (FDCA) advertising standards in relation to print ads for bupropion hydrochloride extended-release tablets (SR).
The FDA will not change its warnings for pregnant women taking certain anti-hypertension medicines -- even though a study it cosponsored shows an elevated risk of birth defects in the first trimester.
Decision Resources, Inc., one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that sustained annual growth of more than 3.4% in sales of prostate cancer therapies from 2005 to 2015 will be driven primarily by new entries to the market that will add to, rather than replace, existing therapies in the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan.